critical early step that significantly influences the success of subsequent trial phases. This article provides an end-to-end process guide tailored for clinical operations, regulatory affairs, and medical affairs professionals working in the US, UK, and EU. It covers the entire lifecycle from initial concept through to close-out, emphasizing operational execution and regulatory compliance. Understanding how to effectively conduct clinical trial site feasibility assessments, design and utilize feasibility questionnaires, and integrate these findings into trial planning is essential for meeting the expectations of regulatory authorities such as the FDA, EMA, and MHRA, as well as adhering to ICH guidelines. This guide aims to enhance professional training and operational readiness in clinical trial feasibility activities, ensuring robust study design and regulatory alignment.

Understanding Feasibility Study Clinical Trials: Context and Core Definitions

A feasibility study clinical trial is a preliminary evaluation conducted to determine whether a proposed clinical trial is practical and viable at selected sites before full-scale initiation. This assessment includes evaluating patient population availability, site infrastructure, investigator experience, and regulatory environment. It is a foundational component of the clinical trial lifecycle, situated between protocol concept development and site initiation.

Key terminology includes:

• Clinical Trial Site Feasibility: The process of assessing individual trial sites for their capability to conduct the study according to protocol and regulatory requirements.
• Feasibility Questionnaire Clinical Trials: Structured surveys or forms used to collect standardized information from potential sites regarding resources, patient access, and prior experience.
• Clinical Trial Feasibility: The overall evaluation of whether the study objectives can be met within defined timelines and budgets, considering operational and regulatory factors.

In practice, feasibility studies inform critical decisions such as site selection, enrollment projections, and risk mitigation strategies. They ensure scientific validity by confirming that the study population and infrastructure align with protocol requirements. From a regulatory perspective, feasibility data supports submissions and inspections by demonstrating due diligence in trial planning, as outlined in ICH E6(R3) guidelines on trial design and site management.

Regulatory and GCP Expectations in the US, EU, and UK

Regulatory agencies emphasize the importance of thorough feasibility assessments as part of Good Clinical Practice (GCP) compliance and trial quality assurance. In the US, the FDA regulations (21 CFR Part 312) require sponsors to ensure investigator qualifications and site suitability, which are informed by feasibility activities.

In the EU, the EU Clinical Trials Regulation (EU-CTR 536/2014) mandates that sponsors provide evidence of site capability and recruitment feasibility during the trial application process. The EMA’s GCP guidelines and the European Medicines Agency’s reflection papers further stress feasibility as a risk mitigation measure.

The UK’s MHRA similarly expects sponsors to conduct comprehensive feasibility assessments to confirm site readiness and patient availability, aligning with the UK GCP Guide and the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended).

Across all regions, adherence to ICH E6(R3) and E8(R1) guidelines on trial design and site management underpins regulatory expectations. These documents highlight feasibility as a critical element to ensure trial integrity, participant safety, and data reliability. Sponsors and CROs must operationalize these expectations through documented procedures and training, ensuring that feasibility assessments are systematic, documented, and auditable.

Practical Design and Operational Considerations for Feasibility Study Clinical Trials

Designing and executing a feasibility study clinical trial requires a structured approach integrating scientific, operational, and regulatory inputs. The following steps outline best practices:

1. Define Feasibility Objectives: Clarify what the feasibility study aims to assess—patient recruitment potential, site capabilities, regulatory landscape, or all combined.
2. Develop Feasibility Questionnaires: Create standardized questionnaires tailored to capture critical data such as patient demographics, prior trial experience, staffing, equipment, and data management capabilities.
3. Identify and Engage Potential Sites: Use internal databases, investigator networks, and external site identification tools to select candidate sites for feasibility assessment.
4. Conduct Site Feasibility Assessments: Administer questionnaires and follow up with interviews or site visits as needed to validate responses and clarify constraints.
5. Analyze Feasibility Data: Aggregate responses to evaluate recruitment timelines, resource gaps, and potential risks. Use this data to refine protocol design or site selection.
6. Document Findings and Decisions: Maintain comprehensive records of feasibility assessments to support regulatory submissions and audit trails.

Operationally, sponsors typically delegate feasibility activities to clinical operations teams or CROs, with oversight from regulatory and medical affairs to ensure compliance and scientific rigor. Principal Investigators (PIs) and site staff provide critical input on local patient populations and operational constraints. For example, the CodeBreak 100 trial utilized a robust feasibility questionnaire clinical trials approach to optimize site selection and enrollment strategies across multiple regions.

Common Pitfalls, Inspection Findings, and How to Avoid Them

Regulatory inspections frequently identify deficiencies related to feasibility assessments that can jeopardize trial integrity. Common pitfalls include:

• Inadequate Documentation: Failure to maintain detailed records of feasibility questionnaires and site evaluations undermines transparency and audit readiness.
• Overestimating Recruitment Potential: Sites may overstate patient availability, leading to enrollment delays and protocol amendments.
• Ignoring Site Infrastructure Limitations: Insufficient assessment of site resources such as equipment, staff qualifications, or data management capabilities can cause compliance issues.
• Lack of Regulatory Alignment: Feasibility processes not aligned with regional regulatory expectations may result in application delays or inspection findings.

To mitigate these risks, teams should implement robust Standard Operating Procedures (SOPs) for feasibility assessments, provide targeted training on questionnaire design and site engagement, and establish metrics to monitor recruitment projections against actual enrollment. Regular quality checks and cross-functional reviews involving clinical, regulatory, and medical affairs enhance data integrity and compliance.

US vs EU vs UK Nuances and Real-World Case Examples

While the core principles of clinical trial feasibility are consistent across the US, EU, and UK, regional nuances affect implementation:

• US (FDA): Emphasizes investigator qualifications and site compliance history, with a focus on 21 CFR Part 312 adherence. Feasibility assessments often integrate with Investigational New Drug (IND) application planning.
• EU (EMA/EU-CTR): Requires detailed feasibility data as part of the centralized trial application, with heightened scrutiny on patient recruitment feasibility and multi-state site coordination.
• UK (MHRA): Post-Brexit, the MHRA maintains alignment with ICH guidelines but requires separate submissions and local feasibility considerations, particularly for sites outside England.

Case Example 1: A multinational oncology trial encountered recruitment delays due to over-optimistic site feasibility assessments in the EU. Subsequent re-assessment using a refined feasibility questionnaire clinical trials tool improved site selection and enrollment rates.

Case Example 2: The CodeBreak 100 trial, conducted across US and UK sites, demonstrated effective harmonization of feasibility processes by integrating regulatory requirements from both regions into a unified feasibility assessment framework, reducing start-up timelines and inspection findings.

Implementation Roadmap and Best-Practice Checklist

To operationalize a robust feasibility study clinical trial process, clinical teams should follow this stepwise roadmap:

1. Establish Feasibility SOPs: Develop and approve procedures detailing feasibility assessment methods, documentation standards, and roles.
2. Train Cross-Functional Teams: Conduct targeted training for clinical operations, regulatory affairs, and medical affairs on feasibility concepts and tools.
3. Design Feasibility Tools: Create or adapt feasibility questionnaires and site evaluation templates aligned with regulatory expectations.
4. Identify Candidate Sites: Use data-driven approaches and investigator networks to shortlist potential sites.
5. Execute Feasibility Assessments: Administer questionnaires, conduct interviews, and perform site visits as appropriate.
6. Analyze and Document Results: Aggregate data to inform site selection, protocol adjustments, and risk management plans.
7. Integrate Findings into Trial Planning: Update timelines, budgets, and regulatory submissions based on feasibility outcomes.
8. Monitor Recruitment and Site Performance: Establish metrics to compare feasibility projections against actual performance during trial conduct.

Below is a checklist summarizing key actions for clinical trial teams:

• Develop and maintain comprehensive feasibility SOPs covering all aspects of site and trial feasibility.
• Utilize standardized feasibility questionnaires clinical trials to ensure consistent data collection.
• Engage sites early with clear communication on feasibility requirements and expectations.
• Document all feasibility findings thoroughly to support regulatory submissions and audits.
• Align feasibility processes with FDA, EMA/EU-CTR, and MHRA regulatory frameworks and ICH guidelines.
• Incorporate cross-functional reviews involving clinical, regulatory, and medical affairs teams.
• Regularly update feasibility assessments in response to evolving trial conditions or regulatory feedback.

Comparison of Feasibility Study Clinical Trial Requirements: US, EU, and UK

Aspect	US (FDA)	EU (EMA/EU-CTR) & UK (MHRA)
Regulatory Framework	21 CFR Part 312, ICH E6(R3)	EU-CTR 536/2014, UK GCP Guide, ICH E6(R3)
Feasibility Documentation	Investigator qualifications, site history, recruitment potential	Site capability, patient population data, multi-state coordination
Submission Requirements	Included in IND application and site initiation packages	Required as part of centralized trial application and local approvals
Site Engagement	Focus on investigator compliance and site readiness	Emphasis on harmonized site capability across countries
Inspection Focus	Documentation completeness, recruitment feasibility accuracy	Feasibility data consistency, regulatory alignment, and site preparedness

Key Takeaways for Clinical Trial Teams

• Conducting a thorough feasibility study clinical trial is essential to ensure realistic recruitment targets and site readiness, directly impacting trial success.
• Align feasibility assessments with ICH guidelines and regional regulatory expectations to mitigate inspection risks and support regulatory submissions.
• Implement standardized feasibility questionnaires clinical trials and SOPs, coupled with cross-functional training, to enhance data quality and operational consistency.
• Recognize and adapt to US, EU, and UK regulatory nuances by harmonizing feasibility processes in multinational trials to optimize timelines and compliance.